Bioharvest Sciences (BHST) Current Deferred Revenue (2023 - 2025)

Bioharvest Sciences' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $492000.0 for Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 45.7% year-over-year to $492000.0 in Q4 2025; TTM through Dec 2025 was $492000.0, a 45.7% decrease from a year earlier, with the FY2025 full-year figure at $492000.0, down 45.7% from the prior year.
• Current Deferred Revenue improved to $492000.0 in Q4 2025 per BHST's latest filing, from $438000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.1 million in Q1 2025 and bottomed at $438000.0 in Q3 2025.
• The 3-year median for Current Deferred Revenue is $906000.0 (2024), against an average of $797000.0.
• Across the five-year window, Current Deferred Revenue gained 26.18% in 2024 and plunged 45.7% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $718000.0 in 2023, then climbed by 26.18% to $906000.0 in 2024, then plunged by 45.7% to $492000.0 in 2025.
• Per Business Quant, the three latest BHST Current Deferred Revenue figures stand at $492000.0 (Q4 2025), $438000.0 (Q3 2025), and $990000.0 (Q2 2025).